MN1 alterations have emerged as potential prognostic markers, with studies indicating improved PSF and OS in gliomas exhibiting MN1 rearrangements.150,151 Compared with BRAF V600E-mutated pleomorphic xanthoastrocytomas, MN1-rearranged astroblastomas have a more favorable prognosis.152 However, the mechanistic role of MN1 in tumorigenesis remains unclear, necessitating further studies to elucidate its functional impact on glioma biology and its potential utility in guiding clinical decision-making. This evidence concerns the gene BRAF and central nervous system cancer.